

### medicare



## Severe chronic plaque psoriasis – continuing authority application

#### When to use this form

Use this form to apply for **continuing** PBS-subsidised biological medicines for patients 18 years or over with severe chronic plaque psoriasis.

#### **Important information**

**Continuing** authority applications must be in writing and must include sufficient information to determine the patient's eligibility according to the PBS criteria.

Applications for **balance of supply** can be made in real time using the **Online PBS Authorities** system or by phone. Call 1800 700 270 Monday to Friday, 8 am to 5 pm, local time.

Under no circumstances will phone approvals be granted for severe chronic plaque psoriasis **continuing** authority applications.

Where the term 'biological medicine' appears, it refers to adalimumab, bimekizumab, etanercept, guselkumab, infliximab, ixekizumab, risankizumab, secukinumab, tildrakizumab and ustekinumab.

A copy of the PASI calculation sheets is provided for your convenience.

The information in this form is correct at the time of publishing and may be subject to change.

#### **Continuing treatment**

This form is ONLY for **continuing** treatment.

The patient remains eligible to receive **continuing** treatment providing they continue to sustain a response to treatment.

After a written authority application for the **first continuing** treatment has been approved, **subsequent continuing** treatments with PBS-subsidised biosimilar brands of biological medicines are **Authority Required (STREAMLINED)** and do not require authority approval from Services Australia for the listed quantity and repeats.

### Section 100 arrangements for infliximab i.v. only

This item is available to a patient who is attending:

- an approved private hospital, or
- a public hospital

#### and is a:

- day admitted patient
- non-admitted patient, or
- patient on discharge.

This item is not available as a PBS benefit for in-patients of a public hospital.

The hospital name and provider number must be included in this authority form.

#### **Treatment specifics**

The assessment of the patient's response to the course of treatment must be conducted within the time frame specified in the restriction. Where a demonstration of response is not conducted within the required time frame, the patient will be deemed to have failed treatment with that particular PBS-subsidised biological medicine.

A patient who has experienced a serious adverse reaction of a severity necessitating permanent treatment withdrawal is not considered to have failed treatment with that particular PBS-subsidised biological medicine.

#### For more information

Go to servicesaustralia.gov.au/healthprofessionals

PB113.2405 **1 of 5** 



### medicare



# Severe chronic plaque psoriasis – continuing authority application

Pa	tient's details	Hospital details for infliximab i.v. only		
1	Medicare card number  Ref no.	8 Hospital name		
2	Department of Veterans' Affairs card number  Dr Mr Mrs Miss Ms Other	This hospital is a:  public hospital  private hospital  Hospital provider number		
	Family name	Conditions and criteria		
	First given name	To qualify for PBS authority approval, the foll must be met.	owing conditions	
3	Date of birth (DD MM YYYY)	10 Is the patient, 18 years or over, being treadermatologist?	ated by a	
4	Patient's weight kg	No Yes This application is for:		
Pr	escriber's details	adalimumab		
5 6	Prescriber number  Dr Mr Mrs Miss Ms Other	bimekizumab etanercept guselkumab infliximab i.v. infliximab s.c.		
	Family name  First given name	ixekizumab risankizumab secukinumab tildrakizumab		
7	Business phone number (including area code)  Alternative phone number (including area code)	ustekinumab  12 Has the patient previously received this b (in any form) as their most recent course treatment for this condition?  No  Yes  Dates of the most recent treatment (DD MM YYYY)	of PBS-subsidised ment course	
		T- (DD 844 1988)		

MCA0PB113 2405

3 Is the patient receiving treatment with the as systemic monotherapy (other than me		Prescriber's declaration
No U	,	You do not need to <b>sign</b> the declaration if you complete this form using Adobe Acrobat Reader and return this form through Health Professional Online Services (HPOS) at
The patient has demonstrated or sustain response to treatment confirmed by:  Psoriasis Area and Severity Index (P. 75% or more, or sustained at this le baseline values for this treatment cychronic plaque psoriasis only)  PASI score  Date of assessment (DD MM YYYY)  Or  PASI symptom subscores for all 3 of and scaling have been reduced to sisustained at this level, compared to this treatment cycle (applies to face plaque psoriasis only)  Date of assessment (DD MM YYYY)  Or  or  a reduction by 75% or more in the sisustained at this level, compared to this treatment cycle (applies to face plague psoriasis only)	ASI) score reduced by vel, compared to the vele (for whole body  f erythema, thickness light or better, or the baseline values for hand and foot chronic skin area affected, or the baseline values for	<ul> <li>I declare that: <ul> <li>I am aware that this patient must meet the criteria listed in the current Schedule of Pharmaceutical Benefits to be eligible for this medicine.</li> <li>I have informed the patient that their personal information (including health information) will be disclosed to Services Australia for the purposes of assessing and processing this authority application.</li> <li>I have provided details of the proposed prescription(s) and the relevant attachments as specified in the Pharmaceutical Benefits Scheme restriction.</li> <li>the information I have provided in this form is complete and correct.</li> <li>I understand that:</li> <li>giving false or misleading information is a serious offence.</li> <li>I have read, understood and agree to the above.</li> </ul> </li> <li>Date (DD MM YYYY) (you must date this declaration)</li> <li>Prescriber's signature (only required if returning by post)</li> </ul>
plaque psoriasis only).  Date of assessment (DD MM YYYY)  The PASI assessment must not be <b>olde</b> time of application.	r than 4 weeks at the	Returning this form  Return this form, details of the proposed prescription(s) and any relevant attachments:
The relevant attachments need this form.  Details of the proposed prescriptions The completed PASI calculation sheet	(s).	<ul> <li>online (no signature required), upload through HPOS at servicesaustralia.gov.au/hpos</li> <li>or</li> <li>by post (signature required) to Services Australia Complex Drugs Programs Reply Paid 9826 HOBART TAS 7001</li> </ul>
Privacy notice		HUDANI IAS 7001
Personal information is protected by law Privacy Act 1988) and is collected by Serpurposes of assessing and processing the Personal information may be used by Serpurpose of the parties where the indivior where it is required or authorised by lapurpose of research or conducting investing More information about the way in which manages personal information, including be found at servicesaustralia.gov.au/p	rvices Australia for the his authority application. rvices Australia, dual has agreed to this, aw (including for the tigations).  In Services Australia our privacy policy, can	



### medicare

# PASI calculation and body diagram – face, hand and foot



Body region						
Indicate the degree of	FACE	RIGHT PALM	LEFT PALM	RIGHT SOLE	LEFT SOLE	
involvement of the body region surface as a percentage	%	%	%	%	%	
OR						
Clearly indicate the plaque characteristics for each body region by circling the number which best corresponds to the patient's skin condition (circle one number in each box)						
	0 = none					
	1 = slight					
Erythema	2 = moderate					
	3 = severe					
	4 = very severe					
	0 = none					
	1 = slight					
Thickness	2 = moderate					
	3 = severe					
	4 = very severe					
	0 = none					
	1 = slight					
Scaling	2 = moderate					
	3 = severe					
	4 = very severe					

Mark clearly on the diagrams the extent of the affected area(s)
















# PASI calculation and body diagram – whole body



Diamos abayastavistis	Dating acces	Body region (and weighting factor)				
Plaque characteristic	Rating score	Head	Upper Limbs	Trunk	Lower Limbs	
Erythema	0 = None 1 = Slight					
Thickness	2 = Moderate					
Scaling	3 = Severe 4 = Very severe					
Adı	Add together each of the 3 scores for each of the body regions to give 4 separate sub totals.					
	Sub Totals	A1=	A2=	A3=	A4=	
Multiply each sub total by the amount of body surface area represented by that region i.e. A1 x 0.1 for head, A2 x 0.2 for upper limbs, A3 x 0.3 for trunk, A4 x 0.4 for lower limbs to give a value B1, B2, B3 and B4 for each body region respectively						
		A1 x 0.1 = B1	A2 x 0.2 = B2	A3 x 0.3 = B3	A4 x 0.4 = B4	
		B1=	B2=	B3=	B4=	
Degree of involvement as % for each body region affected (score each region with score between 0–6)	0 = None 1 = 1-9% 2 = 10-29% 3 = 30-49% 4 = 50-69% 5 = 70-89% 6 = 90-100%					
For each body region multiply sub total B1, B2, B3 and B4 by the score (0–6) of the % of body region involved to give 4 subtotals C1, C2, C3 and C4						
		B1 x score = C1	B2 x score = C2	B3 x score = C3	B4 x score = C4	
		C1=	C2=	C3=	C4=	
The patient's PASI score is the sur	404 00 00 04			PASI=		

Shade in the affected areas



© Commonwealth of Australia, Department of Health and Aged Care. This document is based on a work created by Serono Australia Pty Ltd. The Department of Health and Aged Care gratefully acknowledges the assistance of Serono Australia Pty Ltd in granting permission to use its work.